Zacharon Pharmaceuticals, Inc. is a biotechnology company leveraging innovative drug discovery technology to enable an entirely new class of human therapeutics. These novel small molecule therapies target the biosynthesis of glycans, the carbohydrate chains of glycoproteins, proteoglycans, and glycolipids.

Targeting the biosynthesis of glycans provides a broad selection of specific drug targets with applications across a range of diseases. Zacharon has developed innovative glycan-targeted drug discovery technology which for the first time has effectively enabled this therapeutic strategy, providing a powerful and proprietary discovery platform.

By coupling this drug discovery engine to traditional small molecule drug development, Zacharon is creating a broad pipeline of novel therapeutics. Our most advanced programs are in preclinical development with proof of concept demonstrated in oncology and lysosomal storage disease.